Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Buy
55
SBLOF Quote, Financials, Valuation and Earnings
Last price:
$10.03
Seasonality move
:
0%
Day range:
$10.03 - $10.03
52-week range:
$9.36 - $12.57
Dividend yield:
3.39%
P/E ratio:
13.55x
P/S ratio:
1.80x
P/B ratio:
1.63x
Volume:
--
Avg. volume:
7
1-year change:
2.14%
Market cap:
$417.6M
Revenue:
$212.6M
EPS (TTM):
$0.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SBLOF
Shin Nippon Biomedical Laboratories, Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 2.78% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SBLOF
Shin Nippon Biomedical Laboratories, Ltd.
|
$10.03 | -- | $417.6M | 13.55x | $0.14 | 3.39% | 1.80x |
|
HLOSF
Healios KK
|
$2.50 | -- | $288.5M | -- | $0.00 | 0% | 392.54x |
|
PPTDF
PeptiDream Inc.
|
$12.19 | -- | $1.6B | 13.79x | $0.00 | 0% | 13.13x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.19 | -- | $469.7M | -- | $0.00 | 0% | 2.42x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.22 | $17.76 | $44.9B | 180.46x | $0.32 | 4.65% | 1.53x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SBLOF
Shin Nippon Biomedical Laboratories, Ltd.
|
50.17% | 0.116 | 65.84% | 0.62x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SBLOF
Shin Nippon Biomedical Laboratories, Ltd.
|
$24.5M | $2.6M | 6.02% | 11.53% | 4.71% | -- |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Shin Nippon Biomedical Laboratories, Ltd. vs. Competitors
-
Which has Higher Returns SBLOF or HLOSF?
Healios KK has a net margin of 9.43% compared to Shin Nippon Biomedical Laboratories, Ltd.'s net margin of -9751.87%. Shin Nippon Biomedical Laboratories, Ltd.'s return on equity of 11.53% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital SBLOFShin Nippon Biomedical Laboratories, Ltd.43.53% $0.13 $517M HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About SBLOF or HLOSF?
Shin Nippon Biomedical Laboratories, Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Shin Nippon Biomedical Laboratories, Ltd. has higher upside potential than Healios KK, analysts believe Shin Nippon Biomedical Laboratories, Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SBLOFShin Nippon Biomedical Laboratories, Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is SBLOF or HLOSF More Risky?
Shin Nippon Biomedical Laboratories, Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock SBLOF or HLOSF?
Shin Nippon Biomedical Laboratories, Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 3.39%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shin Nippon Biomedical Laboratories, Ltd. pays 42.27% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Shin Nippon Biomedical Laboratories, Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBLOF or HLOSF?
Shin Nippon Biomedical Laboratories, Ltd. quarterly revenues are $56.2M, which are larger than Healios KK quarterly revenues of $128.8K. Shin Nippon Biomedical Laboratories, Ltd.'s net income of $5.3M is higher than Healios KK's net income of $3.8M. Notably, Shin Nippon Biomedical Laboratories, Ltd.'s price-to-earnings ratio is 13.55x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shin Nippon Biomedical Laboratories, Ltd. is 1.80x versus 392.54x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBLOFShin Nippon Biomedical Laboratories, Ltd.1.80x 13.55x $56.2M $5.3M HLOSFHealios KK392.54x -- $128.8K $3.8M
-
Which has Higher Returns SBLOF or PPTDF?
PeptiDream Inc. has a net margin of 9.43% compared to Shin Nippon Biomedical Laboratories, Ltd.'s net margin of -25.38%. Shin Nippon Biomedical Laboratories, Ltd.'s return on equity of 11.53% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital SBLOFShin Nippon Biomedical Laboratories, Ltd.43.53% $0.13 $517M PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About SBLOF or PPTDF?
Shin Nippon Biomedical Laboratories, Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Shin Nippon Biomedical Laboratories, Ltd. has higher upside potential than PeptiDream Inc., analysts believe Shin Nippon Biomedical Laboratories, Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBLOFShin Nippon Biomedical Laboratories, Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is SBLOF or PPTDF More Risky?
Shin Nippon Biomedical Laboratories, Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock SBLOF or PPTDF?
Shin Nippon Biomedical Laboratories, Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 3.39%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shin Nippon Biomedical Laboratories, Ltd. pays 42.27% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Shin Nippon Biomedical Laboratories, Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBLOF or PPTDF?
Shin Nippon Biomedical Laboratories, Ltd. quarterly revenues are $56.2M, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Shin Nippon Biomedical Laboratories, Ltd.'s net income of $5.3M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Shin Nippon Biomedical Laboratories, Ltd.'s price-to-earnings ratio is 13.55x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shin Nippon Biomedical Laboratories, Ltd. is 1.80x versus 13.13x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBLOFShin Nippon Biomedical Laboratories, Ltd.1.80x 13.55x $56.2M $5.3M PPTDFPeptiDream Inc.13.13x 13.79x $29.3M -$7.4M
-
Which has Higher Returns SBLOF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 9.43% compared to Shin Nippon Biomedical Laboratories, Ltd.'s net margin of -24.76%. Shin Nippon Biomedical Laboratories, Ltd.'s return on equity of 11.53% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital SBLOFShin Nippon Biomedical Laboratories, Ltd.43.53% $0.13 $517M SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About SBLOF or SOLTF?
Shin Nippon Biomedical Laboratories, Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Shin Nippon Biomedical Laboratories, Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Shin Nippon Biomedical Laboratories, Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBLOFShin Nippon Biomedical Laboratories, Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is SBLOF or SOLTF More Risky?
Shin Nippon Biomedical Laboratories, Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock SBLOF or SOLTF?
Shin Nippon Biomedical Laboratories, Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 3.39%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shin Nippon Biomedical Laboratories, Ltd. pays 42.27% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Shin Nippon Biomedical Laboratories, Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBLOF or SOLTF?
Shin Nippon Biomedical Laboratories, Ltd. quarterly revenues are $56.2M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Shin Nippon Biomedical Laboratories, Ltd.'s net income of $5.3M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Shin Nippon Biomedical Laboratories, Ltd.'s price-to-earnings ratio is 13.55x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shin Nippon Biomedical Laboratories, Ltd. is 1.80x versus 2.42x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBLOFShin Nippon Biomedical Laboratories, Ltd.1.80x 13.55x $56.2M $5.3M SOLTFNxera Pharma Co., Ltd.2.42x -- $45.8M -$11.3M
-
Which has Higher Returns SBLOF or STMM?
Stemcell Holdings, Inc. has a net margin of 9.43% compared to Shin Nippon Biomedical Laboratories, Ltd.'s net margin of --. Shin Nippon Biomedical Laboratories, Ltd.'s return on equity of 11.53% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBLOFShin Nippon Biomedical Laboratories, Ltd.43.53% $0.13 $517M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About SBLOF or STMM?
Shin Nippon Biomedical Laboratories, Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Shin Nippon Biomedical Laboratories, Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Shin Nippon Biomedical Laboratories, Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SBLOFShin Nippon Biomedical Laboratories, Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is SBLOF or STMM More Risky?
Shin Nippon Biomedical Laboratories, Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBLOF or STMM?
Shin Nippon Biomedical Laboratories, Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 3.39%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shin Nippon Biomedical Laboratories, Ltd. pays 42.27% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Shin Nippon Biomedical Laboratories, Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBLOF or STMM?
Shin Nippon Biomedical Laboratories, Ltd. quarterly revenues are $56.2M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Shin Nippon Biomedical Laboratories, Ltd.'s net income of $5.3M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Shin Nippon Biomedical Laboratories, Ltd.'s price-to-earnings ratio is 13.55x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shin Nippon Biomedical Laboratories, Ltd. is 1.80x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBLOFShin Nippon Biomedical Laboratories, Ltd.1.80x 13.55x $56.2M $5.3M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns SBLOF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 9.43% compared to Shin Nippon Biomedical Laboratories, Ltd.'s net margin of -1.05%. Shin Nippon Biomedical Laboratories, Ltd.'s return on equity of 11.53% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital SBLOFShin Nippon Biomedical Laboratories, Ltd.43.53% $0.13 $517M TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About SBLOF or TAK?
Shin Nippon Biomedical Laboratories, Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 24.69%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Shin Nippon Biomedical Laboratories, Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Shin Nippon Biomedical Laboratories, Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBLOFShin Nippon Biomedical Laboratories, Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is SBLOF or TAK More Risky?
Shin Nippon Biomedical Laboratories, Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock SBLOF or TAK?
Shin Nippon Biomedical Laboratories, Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 3.39%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.65% to investors and pays a quarterly dividend of $0.32 per share. Shin Nippon Biomedical Laboratories, Ltd. pays 42.27% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Shin Nippon Biomedical Laboratories, Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios SBLOF or TAK?
Shin Nippon Biomedical Laboratories, Ltd. quarterly revenues are $56.2M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Shin Nippon Biomedical Laboratories, Ltd.'s net income of $5.3M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Shin Nippon Biomedical Laboratories, Ltd.'s price-to-earnings ratio is 13.55x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 180.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shin Nippon Biomedical Laboratories, Ltd. is 1.80x versus 1.53x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBLOFShin Nippon Biomedical Laboratories, Ltd.1.80x 13.55x $56.2M $5.3M TAKTakeda Pharmaceutical Co., Ltd.1.53x 180.46x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
